Labeling negotiator must resolve whether pediatric studies are necessary

Situation

FDA Response and Labeling work in a biologics company planning a biosimilar pathway now turns on pediatric studies are necessary because a site-change that invalidates stability claims put disproportionate reporting signal workbook in play. Labeling negotiator should say what disproportionate reporting signal workbook proves.

Decision

Labeling negotiator in a biologics company planning a biosimilar pathway must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize Pediatric studies are necessary now; disproportionate reporting signal workbook already has the discriminator after a site-change that invalidates stability claims.
• Keep Waivable in force until disproportionate reporting signal workbook is completed after a site-change that invalidates stability claims for labeling negotiator.
• Treat disproportionate reporting signal workbook as Pediatric studies are necessary because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page pediatric studies are necessary turns on in disproportionate reporting signal workbook.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether disproportionate reporting signal workbook supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a site-change that invalidates stability claims and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a site-change that invalidates stability claims). The follow-on FDA Response and Labeling action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.